Amino acid derivatives as histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 1, 2008, Pages 34-38

  Hubbs, Jed L ^a   Zhou, Hua ^a   Kral, Astrid M ^a   Fleming, Judith C ^a   Dahlberg, William K ^a   Hughes, Bethany L ^a   Middleton, Richard E ^a   Szewczak, Alexander A ^a   Secrist, J Paul ^a   Miller, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amino acid; Benzothiophene; Cancer; Histone deacetylase; Lysine; Ugi reaction

Indexed keywords

AMINO ACID DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PHENYLGLYCINE; PIPERAZINE DERIVATIVE; VORINOSTAT;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG DESIGN; DRUG INDICATION; DRUG STRUCTURE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; SKIN LYMPHOMA; T CELL LYMPHOMA;

AMINO ACIDS; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 37549066329     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.017     Document Type: Article

References (12)

1. Rodriquez M., Aquino M., Bruno I., De Martino G., Taddei M., and Gomez-Paloma L. Curr. Med. Chem. 13 (2006) 1119
2. Dokmanovic M., and Marks P.A. J. Cell. Biochem. 96 (2005) 293
3. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Exp. Hematol. 33 (2005) 53
4. Hamblett C.L., Methot J.L., Mampreian D.M., Sloman D.L., Stanton M.G., Kral A.M., Fleming J.C., Cruz J.C., Chenard M., Ozerova N., Hitz A.M., Wang H., Deshmukh S.V., Nazef N., Harsch A., Hughes B., Dahlberg W.K., Szewczak A.A., Middleton R.E., Mosley R.T., Secrist J.P., and Miller T.A. Bioorg. Med. Chem. Lett. 17 (2007) 5300
5. Arts J., de Schepper S., and Emelen K.V. Curr. Med. Chem. 10 (2003) 2343
6. Grant S., Easley C., and Kirkpatrick P. Nat. Rev. Drug Disc. 6 (2007) 21
7. Miller T.A., Witter D.J., and Belvedere S.J. J. Med. Chem. 46 (2003) 5097
8. Belvedere S., Witter D.J., Yan J., Secrist P., Richon V., and Miller T.A. Bioorg. Med. Chem. Lett. 17 (2007) 3969
9. Witter D.J., Belvedere S., Chen L., Secrist P., Mosley R.T., and Miller T.A. Bioorg. Med. Chem. Lett. 17 (2007) 4562
10. Ugi I., Meyr R., Fetzer U., and Steinbruckner C. Angew. Chem. 71 (1959) 386
11. All diaminobenzene derivatives are less potent than hydroxamic acid 4, this is consistent with previous results which suggest that hydroxamic acids are more potent HDAC1 inhibitors.
12. Siliphaivanh P., Harrington P., Witter D.J., Otte K., Tempest P., Kattar S., Fleming J.J., Deshmukh S.V., Harsch A., Secrist P.J., and Miller T.A. Bioorg. Med. Chem. Lett. 17 (2007) 4619